Caveolin-1 (Cav-1) is 22 kDa caveolae protein, acts as a scaffold within caveolar membranes.
Introduction
Prostate cancer is the third most common cancer and the second leading cause of death in males in the western countries 1 , and surgery or radiotherapy is generally used to treat prostate adenocarcinoma. This non-localized disease generally erupts during the course of androgen suppression at the start of the primary therapy 2 . Till now, not a single effective therapeutic strategy is available after the failure of the primary treatment. Earlier studies have identified a large number of candidate genes involved in prostate cancer metastasis 3 . Caveolin-1 (Cav-1)
has been found upregulated in mouse cell lines with metastatic prostate cancer 4 . Cav-1 is a 21-24 kDa multi-functional signalling protein and lipid transporter 5 . Caveolae, which are specialized plasma membrane invaginations, found in smooth muscle cells, adipocytes and endothelium, comprises Cav-1 as its major structural component 6 . Cav-1 mediated oncogenic mechanisms in prostate cancer involves two pathways, first, interaction of enhanced Cav-1 expression with cellular signalling factors to stimulate the proliferation and activation of antiapoptotic mechanisms 7 . Also, PI3K/Akt pathway remains constantly active in cultured prostate cancer cells because of the binding of upregulated Cav-1 to protein phosphatases PP1 and PP2A 8 . The progression and development of prostate tumors is significantly reduced in Cav-1 negative mice, and prostatic hyperplasia is caused in prostatic epithelial cells due to overexpression of Cav-1 9 . Second, Cav-1 secreted by the prostate cancer cells into the tumor micro-environment promotes the cell growth and angiogenesis 10, 11 . Elevated Cav-1 in the metastasis-derived cells suggests that Cav-1 is correlated with prostate cancer metastasis 8, 9 .
Cav-1 has been found as a potential therapeutic target for the prostate cancer metastasis 12 .
Unfortunately, almost all the therapies of prostate cancer are associated with various side effects. Natural compounds have been found very effective from ancient time to treat various types of cancers and warrants for the identification of therapeutic natural compounds against prostate cancer.
As the drug discovery process is exhaustive, labour intensive, expensive and time consuming, in silico studies offer a cost effective platform for the discovery of 'active' molecules. In-silico analysis was performed earlier using different therapeutic targets 13 .
In the present study, in silico analyses were performed to discover natural compounds as Cav-1 inhibitor. Although, the crystal structure of Cav-1 has not been yet resolved. However, protein structure predictions were done to perform the current study. Virtual screening and induced fit docking (IFD) were performed for the identification of Cav-1 inhibitors. Molecular dynamics (MD) simulation was carried out to decipher the interaction pattern and stability of ligand-Cav-1 complex. Protein-protein interaction (PPI) network of Cav-1 was generated for the elucidation of the interacting proteins. Overall, the present study offers a sturdy platform for the prospective experimental validations of Cav-1 inhibitor(s) for therapeutic applications against prostate cancer based on the predictive findings obtained from this potential in silico study.
Results and Discussion

Protein Structure Prediction and Validation
BLAST search was performed for human Cav-1 (178 amino acid) in order to search the suitable template for the structure prediction as done in other similar studies executed in bacterial disease 14 . Based on the results of BLAST analysis, sequence similarity was observed too low for the homology modelling, so structure prediction was done using I-Tasser server. Structure validation of the generated model showed a good quality of the predicted model (Table 1) . 3D-structure of the predicted model is shown in Figure 1 . Ramachandran plot analysis suggested that the predicted model has 93.1% residues in the most favoured regions indicating the good quality of the model, as a good quality model is supposed to have more than 90% of its residues in the most favoured regions. The generated model passed through PROVE program with 1.631 Z-score RMS. Overall ERRAT (protein structure verification algorithm well suited for evaluation of crystallographic model building and refinement) quality factor value was 72.95%.
All validation results strongly favoured the acceptance reliability of the predicted 3D model.
Active Site Prediction
Active site(s) were predicted using Sitemap. Two drug able sites were generated with good site scores (0.912 and 0.898). Actives site having site score 0.912 were selected for further docking studies.
Molecular Docking and Virtual Screening
A recent study demonstrated that virtual screening is more significant than high-throughput screening because of less time consumption and cost effectiveness 15, 16 . Receptor-based virtual screening for various targets including proteases has demonstrated the success rate of in silico studies 17 . The structure-based virtual screening methodology remains highly desirable for the identification of novel compounds with structural diversity, as the active site of the protein serves as a target 18 . In the present study, ZINC compounds optimized with the OPLS-2005
force field were subjected to ADME filters to reduce the false-positives and to avoid poor pharmacokinetic profiles. In addition, Lipinski rule of five was calculated applying cut-off range of the removal of the outliers 19 . By strictly following the above mentioned criteria and filters, the Zbc library was compressed to 164530 compounds, which were then subjected to a stepwise high throughput virtual screening (HTVS) protocol 20 . Initially, the standard precision (SP) and extra-precision (XP) docking were performed to calculate the Glide score and Glide energy. MAP kinase (16) . Hence, in the present study, we have ranked the inhibitors based on their glide score.
Binding Energy Calculation
In MM/GBSA score analysis was performed to determine the binding efficiency using the pose viewer file of the protein-ligand complex generated from XP docking. The estimated efficiencies of the hit compounds ZINC13410492, ZINC08298670, ZINC13550046, ZINC01535903 and ZINC13431926 were found to be -63.345, -58.716, -46.152, -55.253 and-59.28 kcal/mol, respectively (Table 2) .
Protein−Ligand Complex Simulation
During the flexible docking, protein receptor was considered rigid in nature. To investigate the dynamic stability and interaction pattern of the ligand-protein complex, molecular dynamics simulation was performed for 100 ns. ZINC13410492-Cav-1 complex having highest Glide score was considered for this simulation study. Conformational links of the system were monitored using the root mean-square deviation (RMSD) values of C-alpha atoms. Figure 4 shows the RMSD values of ZINC13410492 system for 100 ns MD simulation. Trajectories analysis revealed that ZINC13410492 system was stable and well within the binding pocket of found to be 9.283 (reference range 7.9 to 10.5) and -0.217 (reference range -0.9 to 1.7), respectively. Also, the compound (ZINC13410492) was found to be satisfactory according to
Jorgensen rule of three infringement and Lipinski rule of five.
Protein-Protein Interaction Network
The PPI network was constructed with 11 nodes and 32 edges based on the information In conclusion, Cav-1 is a potential target for anti-cancer drug designing and virtual screening can act as a potential step towards the development of new therapy against prostate cancer.
Novel inhibitors were identified by in silico screening of biogenic compounds from the ZINC database using induced fit docking programs. Strong binding affinity of the selected compounds was predicted for Cav-1 by docking studies. The selected compound (ZINC13410492) was further validated by MD simulations. Cav-1 has been found an important protein which involve in a number of signalling pathways to control the cell progression.
Overall, our current in silico findings offers a solid background for the future experimental validations of Cav-1 inhibitor(s) for prostate cancer therapy.
Material and Methods
Protein Structure Prediction and Validation
Due to non-availability of the three dimensional (3D) structure of Cav-1 in the protein data bank (PDB) 24 , the 3D-structure of Cav-1 was generated from the primary sequence retrieved from UniProt knowledge database. The primary sequence of human Cav-1 was extracted (UniProt Id: Q03135) and the sequence was searched against PDB entries using protein-protein BLAST to identify the template crystal structure. The 3D-structure of Cav-1 was predicted by I-Tasser server (Iterative Threading Assembly Refinement), based on multiple threading approach followed by full-length atomic model construction employing iterative template fragment assembly simulations [25] [26] [27] [28] . The quality of the generated model was evaluated by using PROCHECK 29 , PROVE 30 and ERRAT 31 programs.
Protein Preparation and Structure Refinement
The modelled 3D structure of Cav-1 was prepared by using protein preparation wizard of the Schrodinger Suite 32 to ensure the quality and reliability of the structure. Protein optimization and minimization was done by employing OPLS (Optimized Potentials for Liquid Simulations)
2005 force field.
Active-Site Prediction
Sitemap was employed to predict the interacting residues as it provides indications and pertinent information about the suitable position for the donor or the acceptor or the hydrophobic group in the receptor. The physical parameters selected for describing the drug ability included hydrophilicity, degree of exposure, hydrophobicity, hydrogen bonding and binding site points.
High Throughput Virtual Screening
ZINC biogenic compounds (Zbc), a commercially available primary and secondary metabolite database, originally includes 189466 compounds was prepared by using OPLS 2005 force field 33 . Zbc compounds have been used to identify the mitogen activated protein kinase inhibitors 34 . The 3D-structures of the small molecules were prepared by using LigPrep 3.5 module before the docking to obtain different stereochemical, tautomeric, and ionization conformer with minimum energy state of the ligands 35, 36 . The prepared database was subjected for the virtual screening workflow (VSW). Prior to the VSW, receptor grid was generated using Glide 6.8 module
37
. The prepared 3D structure of the target protein was used to generate the glide scoring grid for the successive docking calculations. In the VSW, ADME (absorption, distribution, metabolism and excretion) properties were calculated using Qikprop 4.5 module.
In general, the ADME descriptors 38 are calculated at the last stage of the drug discovery process, but in the present study, the ADME properties calculations were performed in the preliminary stage to save the time as well as to curtail the cost involved in the process.
Binding Free Energy Calculation
Generally, the calculations of binding energy are termed to be accurate when compared to the docking energy calculations 39 . Therefore, in the present study, the MMGBSA algorithm in the 
Induced-Fit Docking
In order to avoid the misleading results that might be obtained from the standard docking protocol, IFD was performed by using Glide and Prime modules of Schrodinger Suite for the top five hit compounds obtained from XP docking. The vdW radii having value of 0.5 was used for non-polar atoms of the ligand and receptor, having partial atomic charge less than 0.15 and 0.25 for the ligand and receptor, respectively. Prime refinement was done for the residues present within 5Å range from the ligand. The best complex was re-docked with Glide XP.
Molecular Dynamics Simulation
Prior to MD simulation, XP docked complexes were prepared in the same manner as prepared earlier for the virtual screening. MD simulations were performed to obtain the most stable conformation of Cav-1 and ligand complex. 
